Related references
Note: Only part of the references are listed.Rhabdomyolysis and Hepatoxicity From Valproic Acid: Case Reports
Cucnhat P. Walker et al.
JOURNAL OF PHARMACY PRACTICE (2021)
Valproic Acid and the Liver Injury in Patients with Epilepsy: An Update
Hong-Li Guo et al.
CURRENT PHARMACEUTICAL DESIGN (2019)
Valproic Acid and Epilepsy: From Molecular Mechanisms to Clinical Evidences
Michele Romoli et al.
CURRENT NEUROPHARMACOLOGY (2019)
Drug-induced acute liver failure in children and adults: Results of a single-centre study of 128 patients
Harshad Devarbhavi et al.
LIVER INTERNATIONAL (2018)
Drug-Induced Liver Injury: Why is the Roussel Uclaf Causality Assessment Method (RUCAM) Still Used 25 Years After Its Launch?
Gaby Danan et al.
DRUG SAFETY (2018)
A History of the Pharmacological Treatment of Bipolar Disorder
Francisco Lopez-Munoz et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
CSH guidelines for the diagnosis and treatment of drug-induced liver injury
Yue-cheng Yu et al.
HEPATOLOGY INTERNATIONAL (2017)
The pharmacogenomics of valproic acid
Miao-Miao Zhu et al.
JOURNAL OF HUMAN GENETICS (2017)
Role of Inflammatory and Oxidative Stress, Cytochrome P450 2E1, and Bile Acid Disturbance in Rat Liver Injury Induced by Isoniazid and Lipopolysaccharide Cotreatment
Hozeifa Mohamed Hassan et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Valproic Acid and Fatalities in Children: A Review of Individual Case Safety Reports in VigiBase
Kristina Star et al.
PLOS ONE (2014)
Alcoholic disease: Liver and beyond
Alba Rocco et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
Adverse drug reactions induced by valproic acid
Radu M. Nanau et al.
CLINICAL BIOCHEMISTRY (2013)
Non-Fatal and Fatal Liver Failure Associated with Valproic Acid
M. M. Schmid et al.
PHARMACOPSYCHIATRY (2013)
Influence of UDP-glucuronosyltransferase polymorphisms on valproic acid pharmacokinetics in Chinese epilepsy patients
Xiao-Man Chu et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2012)
A new approach on valproic acid induced hepatotoxicity: Involvement of lysosomal membrane leakiness and cellular proteolysis
Jalal Pourahmad et al.
TOXICOLOGY IN VITRO (2012)
Case Definition and Phenotype Standardization in Drug-Induced Liver Injury
G. P. Aithal et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Mechanisms and cell signaling in alcoholic liver disease
Juliane I. Beier et al.
BIOLOGICAL CHEMISTRY (2010)
A Pharmacovigilance Program From Laboratory Signals for the Detection and Reporting of Serious Adverse Drug Reactions in Hospitalized Patients
E. Ramirez et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
POLG DNA testing as an emerging standard of care before instituting valproic acid therapy for pediatric seizure disorders
Russell P. Saneto et al.
SEIZURE-EUROPEAN JOURNAL OF EPILEPSY (2010)
Influence of CYP2C9 polymorphism on metabolism of valproate and its hepatotoxin metabolite in Iranian patients
Noushin Amini-Shirazi et al.
TOXICOLOGY MECHANISMS AND METHODS (2010)
Antiepileptic drugs - best practice guidelines for therapeutic drug monitoring: A position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies
Philip N. Patsalos et al.
EPILEPSIA (2008)
Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9*1/*1 genotype
Tony K. L. Kiang et al.
TOXICOLOGICAL SCIENCES (2006)
Sodium- and magnesium-valproate in vivo modulate glutamatergic and GABAergic synapses in the medial prefrontal cortex
G Gobbi et al.
PSYCHOPHARMACOLOGY (2006)
Pharmacological and therapeutic properties of valproate - A summary after 35 years of clinical experience
E Perucca
CNS DRUGS (2002)
CYP2E1-mediated modulation of valproic acid-induced hepatocytotoxicity
MG Neuman et al.
CLINICAL BIOCHEMISTRY (2001)
Share Paper
